BeatO’s revenue jumped 82.0% to ₹53.0 crore (~$5.5 million) in FY25 from ₹29.1 crore in FY24, its fastest growth since the pandemic, as per Inc42’s compiled filings data. Yet the Delhi NCR-based diabetes-care platform has not closed a fresh equity round since November 2022, and it was still spending close to double what it earned as recently as FY24, when its net loss stood at ₹53.67 crore, wider than the revenue that funded it.
That contradiction sits at the heart of BeatO’s decade-long run: a company that two men built out of their own diabetes diagnoses, that rode COVID-19 into a real business, that raised roughly $47.6 million from marquee healthcare investors, and that is still trying to prove a chronic-care subscription model can turn structurally profitable in a market where most people would rather buy a ₹200 glucometer once than pay for a health app every month.
Quick facts
| Company | BeatO (legal entity: Health Arx Technologies Private Limited) |
| Founded | 2015, New Delhi |
| Founder(s) | Gautam Chopra and Yash Sehgal; Chopra is Co-founder & CEO |
| Businesses | Connected glucometers/CGM, app-based coaching and teleconsultation, medicine and diagnostics marketplace, GLP-1 weight-loss program, “PhyDigital” physical clinics |
| Latest FY revenue | ₹53.0 crore in FY25, up 82.0% year-on-year (as per Inc42) |
| Latest FY profit/loss | Net loss of ₹53.67 crore in FY24 (as per TheKredible); FY25 loss not disclosed in the sources reviewed for this piece |
| Listed | Private — not listed on any stock exchange |
| Market value/last valuation | Reported at $47.9 million as of 27 April 2022 (Inc42); a separate data-model estimate from Tracxn puts it at $89.7 million as of 19 September 2026 — neither figure is a company-confirmed transaction price |
| Key shareholders/CEO | Gautam Chopra (CEO); institutional backers include Lightrock India, Blume Ventures, W Health Ventures, HealthQuad, Orios Venture Partners and Flipkart Ventures |
What BeatO does
BeatO sells a subscription-based way to manage type 2 diabetes and, more recently, GLP-1-assisted weight loss, built around a smartphone-linked glucometer and continuous glucose monitor (CGM). A user buys or is issued the connected device, logs blood-sugar readings through the BeatO app, and is assigned a coach and, where needed, a doctor for teleconsultation. Around that core loop the company has built a marketplace for test strips, diabetes-friendly food, diagnostics and medicine refills, an insurance tie-up, and, since November 2023, a small but growing network of physical “Sugar Clinics” that combine in-person diagnostics with the digital programme. Its customers are overwhelmingly individual, self-paying Indian consumers with type 2 diabetes or pre-diabetes, reached directly rather than through employers or insurers, and its stated ambition — repeated in company materials and by HealthQuad, one of its investors — is to reach the roughly 80% of India’s diabetics who live outside the metro hospitals that dominate specialist chronic care.
The origin
Gautam Chopra was working as head of business development and sales steering for Lufthansa in Brussels when he was diagnosed with pre-diabetes in his early thirties. Yash Sehgal, a school friend, had type 2 diabetes. Neither found an Indian product that did more than let them log a number after a finger-prick test; the country’s diabetes care was split between an annual doctor visit, a pharmacy counter and whatever the patient could piece together themselves. In 2015 Chopra left Lufthansa and returned to India, and together with Sehgal he built BeatO first as a simple content and logging app, on the theory that people newly diagnosed with a lifelong condition needed daily engagement, not an annual check-up. As Chopra put it in a 2021 interview, “both of us, as users, were customers 1 and 2 for BeatO” — the founders were also the first people the product had to work for. The company’s name plays on the idea of a blood-sugar reading brought under control, rendered as a blue circle, the international symbol for diabetes.
The product’s shape changed quickly once the app existed: logging blood sugar by hand did not create the habit loyalty a subscription business needs, so BeatO added its own IoT-enabled glucometer that talked directly to the app, and then layered subscription coaching, telemedicine and a strips-and-supplies marketplace around the hardware. That accretive build — content, then device, then care programme, then marketplace, then clinics — is the shape the company still has a decade on.
The struggle years
BeatO’s setbacks were not near-death moments so much as a slow-burning cost problem that took years to bring under control, and the filings lay it out with little room for interpretation. In FY21 the company was still a modest operation — ₹7.97 crore in revenue against a ₹15.25 crore loss — small enough that the burn was survivable on seed and pre-Series A money. FY22 broke that pattern: revenue rose 2.4 times to ₹19.4 crore, but the loss rose three times faster, to ₹46.5 crore, as the company spent ₹3.47 for every rupee of revenue it earned, according to Entrackr’s analysis of its financial statements. Cost of procurement (largely the hardware and strips) rose 3.4 times to ₹25 crore, employee costs more than doubled to ₹15.43 crore, and promotional spending rose 4.4 times to ₹13.32 crore — a company buying growth faster than it could afford it.
FY23 did not bring relief. According to TheKredible’s reporting on BeatO’s FY23 financial statements, losses widened a further 21% to roughly ₹56.3 crore as expenses climbed 17% to about ₹79 crore, even as revenue growth stayed muted. For a company that had raised its marquee $33 million Series B only months earlier, in November 2022, this was the uncomfortable middle of the funding-winter years: Indian venture capital tightened sharply through 2023, and BeatO — like many Series B-stage healthtech firms — had to prove it could survive on the capital already on its balance sheet rather than assume a follow-on round. As of September 2026, public records show no equity financing event since that November 2022 Series B; the two debt facilities that followed, in April and September 2022, do not reappear as a pattern of further debt or equity raises in the years after.
The company’s own response, visible in the numbers, was to slow the burn rather than the growth: FY24 losses narrowed to ₹53.67 crore even as revenue rose to ₹29.1 crore, and FY25 revenue rose again to ₹53.0 crore — the first year in which revenue growth clearly outran the historical pace of loss growth. That is a real improvement, but it is improvement from a low base, three fiscal years after the funding tightened.
The turning point
The single event that changed BeatO’s trajectory was not a funding round; it was the first wave of COVID-19 in India in 2020. Before the pandemic, BeatO was a niche app with a real but slow-growing user base. Once national and regional lockdowns made routine doctor visits difficult for people managing a chronic condition, remote monitoring stopped being a convenience and became, for many diabetics, the only practical option. By the time the company raised its pre-Series B round in July 2021, it was reporting that sales had grown four times versus the pre-COVID period, that usage frequency was up 40%, and that revenue had grown 600% in the trailing period, taking its annualised gross revenue run-rate to about $10 million, according to the company’s own funding announcement carried by PRNewswire. On the ground, that translated into roughly 500,000 app installs and 300,000 paying members by mid-2021, adding 25,000 to 35,000 new paying users a month — a scale-up that, on the other side of the pandemic, gave BeatO the user base and revenue run-rate to raise a $5.7 million round led by W Health Ventures in July 2021 and, sixteen months later, the $33 million Series B that remains its largest round to date.
The money behind it
BeatO has raised roughly $47.6 million (~₹457 crore, at $1 ≈ ₹96.0 as of 18 September 2026, Trading Economics) across six disclosed funding events since 2018, per Inc42’s and Entrackr’s funding records. The rounds:
- April 2018 — $1.3 million seed round led by Blume Ventures, with Leo Capital (Entrackr, 5 April 2018).
- March 2019 — ₹11.5 crore (~$1.6-1.7 million) pre-Series A led by Orios Venture Partners (Entrackr, 20 March 2019).
- July 2021 — ₹42 crore (~$5.7 million) pre-Series B led by W Health Ventures, with participation from PharmEasy (Entrackr and PRNewswire, 7 July 2021).
- April 2022 — ₹27 crore in debt financing led by Kotak Investment Advisors (Entrackr, 27 April 2022).
- September 2022 — a further debt facility from Alteria Capital (Inc42 funding records).
- November 2022 — $33 million Series B led by Lightrock India, with HealthQuad and Flipkart Ventures participating — BeatO’s largest round to date and its last disclosed equity raise as of September 2026 (Entrackr, 16 November 2022).
Three backers stand out for what they changed. Blume Ventures came in at seed stage and stayed through the cap table’s later rounds, giving the founders an anchor investor with a long horizon. W Health Ventures, a US healthcare-focused fund, led the pre-Series B in the immediate aftermath of BeatO’s COVID-driven growth spurt, effectively underwriting the thesis that the pandemic bump was durable rather than a one-off. Lightrock India’s $33 million Series B, more than five times the size of any previous round, funded the shift from being primarily an app-and-device business into the multi-format “phygital” model — teleconsultation, marketplace and physical clinics — that BeatO has built since. On valuation, the only figures on record are estimates rather than disclosed transaction prices: Inc42 put BeatO’s value at $47.9 million as of 27 April 2022, while Tracxn’s cap-table model separately estimates $89.7 million as of 19 September 2026. Both are third-party estimates; BeatO has not publicly confirmed either number, so they are best read as a wide, reported range rather than a fact.
How it makes money
BeatO earns from four linked revenue lines, each layered on top of the device that gets a user into the app in the first place:
- Hardware and consumables: the connected glucometer itself (an entry kit was priced at roughly ₹550 in 2021) and test strips, priced by the company at around ₹10 each, which it has marketed as 40-50% cheaper than incumbent brands (MediaBrief interview with Gautam Chopra, 31 May 2021).
- Subscription care programmes: tiered monthly plans, reported at roughly ₹149 to ₹999 a month in 2021, bundling coaching, structured diabetes or GLP-1 programmes, and monitoring support.
- Teleconsultation and diagnostics: paid doctor consultations (reported at roughly ₹200 to ₹1,000 each in 2021) and diagnostic bookings, plus a medicine and diabetes-supplies marketplace.
- Insurance and clinic tie-ups: a health-insurance partnership with Care Health Insurance disclosed in 2021, a later distribution partnership announced with Policy Ensure in July 2024 aimed at tier-2 and tier-3 cities, and revenue from the physical Sugar Clinics launched from November 2023.
The part people consistently get wrong is treating BeatO as a hardware company. The glucometer is priced to be a low- or negative-margin acquisition tool — cheap enough that cost is not the reason someone skips it — while the actual unit economics depend on converting a device owner into a paying subscriber for coaching, consultations and repeat strip purchases. The FY22 expense breakdown makes the trade-off explicit: procurement (hardware and strips) was the single largest cost line at ₹25 crore, ahead of employee costs, which is what you would expect from a company that is still effectively subsidising the entry device to build the subscriber base that its margin actually depends on.
The numbers
Figures below are as reported in company financial statements analysed by Entrackr and TheKredible; unit is ₹ crore, fiscal year ending 31 March.
| Fiscal year | Revenue (₹ crore) | Net loss (₹ crore) |
|---|---|---|
| FY21 | 7.97 | 15.25 |
| FY22 | 19.4 | 46.5 |
| FY23 | Not disclosed in the sources reviewed | ~56.3 |
| FY24 | 29.1 | 53.67 |
| FY25 | 53.0 | Not disclosed in the sources reviewed |
- FY22: loss was 2.4 times revenue — the company spent ₹3.47 for every rupee earned (Entrackr, 7 March 2023).
- FY23: expenses widened 17% to about ₹79 crore from about ₹67 crore in FY22, even as the loss-to-revenue ratio stayed elevated (TheKredible reporting, FY23 financial statements).
- FY24: loss narrowed year-on-year for the first time in the disclosed record, even as revenue kept climbing — the clearest sign of the post-2022 cost discipline (TheKredible, FY24 financial statements).
- FY25: revenue growth of 82.0% is the fastest rate in the disclosed record, though a matching FY25 loss figure was not available in the sources reviewed for this piece (Inc42 company profile, accessed September 2026).
Where the money comes from
BeatO does not publish an audited geography or product-segment revenue split, so the picture below is built from disclosed milestones and investor commentary rather than a reported percentage breakdown:
- User base grew from roughly 300,000 paying members in mid-2021 (PRNewswire, 7 July 2021) to more than two million app users by November 2023 (BioSpectrum India / DigitalHealthNews, 14 November 2023) — the bulk of BeatO’s addressable revenue still sits in its digital, app-first channel.
- Tier-2/3/4 city expansion is the stated growth frontier, not the metros: HealthQuad, one of BeatO’s investors, frames the opportunity around the “95% of diabetics outside major metros” who lack structured access to specialist diabetes care, and BeatO’s own clinic rollout plan targeted Uttar Pradesh, Madhya Pradesh, Rajasthan, Gujarat and Odisha for expansion beyond its initial five Delhi-NCR clinics (DigitalHealthNews, 14 November 2023).
- Physical “Sugar Clinics” are a newer, smaller channel: five clinics launched in Delhi-NCR on World Diabetes Day, 14 November 2023, with a stated ambition of more than 100 touchpoints nationwide within six months of launch — a target for which no independent confirmation of completion was found in the sources reviewed.
- A GLP-1 weight-loss programme, layered onto the same coaching-and-monitoring infrastructure, is BeatO’s most recent product line, positioned by the company as a doctor-led, prescription-gated service rather than a direct drug-sale channel — a segment too new to have separate disclosed revenue.
- The surprise in the mix is how little of BeatO’s story is really about the glucometer: the device that gave the company its name and its original app-plus-hardware pitch is, on the cost breakdown, run close to cost, while the revenue that actually grew 82% in FY25 comes from the subscription, teleconsultation, marketplace and clinic layers built on top of it.
The risks
- Burn still exceeds revenue. Even after the FY24 improvement, a ₹53.67 crore loss against ₹29.1 crore of revenue means BeatO was still spending roughly ₹1.84 for every rupee earned that year (TheKredible, FY24 financial statements) — a structure that depends on either continued external capital or a further, sustained narrowing of the loss ratio.
- No fresh equity since November 2022. Public funding records (Entrackr, Inc42) show no new equity round after the $33 million Series B, spanning almost four years through the 2023-24 Indian venture funding slowdown; a company at this stage typically needs a Series C to fund the next leg of clinic and geography expansion, and its absence is itself a disclosed data point, not a forecast.
- Crowded, low-switching-cost category. BeatO competes for the same digitally-aware diabetic consumer as other India-focused chronic-care apps and hospital-led programmes, in a market where a basic glucometer from an established medical-device brand can be bought once for a few hundred rupees with no subscription at all — meaning BeatO’s core pitch has to keep justifying a recurring payment against a one-time-purchase alternative.
- Regulatory and data exposure. Connected glucometers, CGMs and the GLP-1 programme sit inside India’s medical-device and telemedicine practice rules, and the platform holds sensitive, continuous health data on people with a chronic condition — any tightening of device certification, telemedicine prescribing rules, or data-protection compliance under India’s DPDP Act adds direct operating cost to a company that is not yet profitable.
The takeaway
BeatO’s decade is a useful corrective to the idea that a personal health crisis and a good app idea are enough. The founders’ own diagnoses gave them a real insight and an early user base that trusted them, and COVID-19 gave the company a genuine, numbers-backed turning point that no marketing budget could have manufactured. But neither of those things solved the harder problem underneath a subscription health business in a price-sensitive market: getting the cost of acquiring and serving each paying member below what that member is willing to pay every month, indefinitely. BeatO’s own filings show it took roughly three fiscal years of widening losses, through the toughest stretch of India’s funding winter, before the loss curve even started bending the right way. The lesson that travels beyond diabetes care is a plain one: a real, personally-felt problem can get a founder in the door, but it does not shorten the years of unglamorous cost discipline needed to make a recurring-revenue health business add up.
Frequently asked questions
Who founded BeatO and when?
BeatO was founded in 2015 in New Delhi by Gautam Chopra and Yash Sehgal, both of whom had personal experience with diabetes or pre-diabetes at the time; Chopra continues to serve as the company’s CEO.
How much funding has BeatO raised?
BeatO has raised roughly $47.6 million (~₹457 crore) across six disclosed funding events between 2018 and 2022, according to Entrackr’s and Inc42’s funding records, with its largest round a $33 million Series B led by Lightrock India in November 2022.
Is BeatO profitable?
No. BeatO has reported a net loss in every fiscal year for which figures are publicly available, including a ₹53.67 crore loss in FY24 against ₹29.1 crore of revenue, though the loss-to-revenue ratio has narrowed from its FY22-FY23 peak, as per TheKredible’s reporting on the company’s financial statements.
What is BeatO’s current valuation?
There is no company-confirmed valuation on record. Inc42 reported a valuation of $47.9 million as of 27 April 2022, while Tracxn’s separate data model estimates $89.7 million as of 19 September 2026; both are third-party estimates rather than disclosed transaction prices.
What does BeatO actually sell?
A connected glucometer or CGM paired with a subscription app, offering blood-sugar tracking, coaching, teleconsultation with doctors, a marketplace for diabetes supplies and medicines, a GLP-1 weight-loss programme, and, since November 2023, a small network of physical “Sugar Clinics” for in-person diagnostics.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Inc42 — BeatO company profile, funding and financial data (accessed September 2026)
- Inc42 — BeatO funding round history and valuation estimate (accessed September 2026)
- Inc42 — BeatO latest news and funding milestone list (accessed September 2026)
- Entrackr — “BeatO’s scale grew 2.4X in FY22, losses shot up 3X” (7 March 2023)
- Entrackr — “BeatO closes $33 Mn Series B round led by Lightrock India” (16 November 2022)
- Entrackr — “BeatO raises Rs 27 Cr in debt” (27 April 2022)
- Entrackr — “BeatO raises Rs 42 Cr in pre-Series B” (7 July 2021)
- Entrackr — “Diabetes mgt app BeatO raises Rs 11.5 Cr pre-Series A round led by Orios VP” (20 March 2019)
- Entrackr — “Blume Ventures and Leo Capital put in $1.3 Mn into healthcare startup BeatO” (5 April 2018)
- TheKredible — BeatO FY23 and FY24 financial statement reporting (2024-2025)
- Tracxn — BeatO shareholding and valuation data (accessed September 2026)
- PRNewswire — “BeatO Raises USD 5.7 Million In Funding Led By W Health Ventures” (7 July 2021)
- MediaBrief — Exclusive interview with Gautam Chopra (31 May 2021)
- HealthQuad — BeatO portfolio profile (accessed September 2026)
- DigitalHealthNews — “Healthtech Startup BeatO Expands Diabetes Care Services with Launch of PhyDigital Clinics across India” (14 November 2023)
- BioSpectrum India — “Delhi-based startup BeatO enters into physical clinics collaborations” (14 November 2023)
- Zaubacorp / MCA corporate records — Health Arx Technologies Private Limited, CIN U74999DL2015PTC284032 (accessed September 2026)
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.